Baxter International Inc (BAX)

BAX on New York Consolidated

72.81USD
17 Apr 2014
Price Change (% chg)

$-0.64 (-0.87%)
Prev Close
$73.45
Open
$73.52
Day's High
$74.00
Day's Low
$72.41
Volume
4,258,274
Avg. Vol
3,639,719
52-wk High
$75.68
52-wk Low
$62.80

BAX

Chart for BAX

About

Baxter International Inc. (Baxter,) is a global, diversified healthcare company. Baxter, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.... (more)

Overall

Beta: 0.73
Market Cap (Mil.): $39,385.54
Shares Outstanding (Mil.): 540.94
Dividend: 0.49
Yield (%): 2.69

Financials

  BAX Industry Sector
P/E (TTM): 19.80 24.12 33.35
EPS (TTM): 3.68 -- --
ROI: -- 11.18 18.92
ROE: -- 13.82 19.68
Search Stocks

U.S. FDA approves Biogen's hemophilia B drug Alprolix

- Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday.

28 Mar 2014

UPDATE 1-U.S. FDA approves Biogen's hemophilia B drug Alprolix

March 28 - Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday.

28 Mar 2014

Fitch Places Baxter International Inc.'s Ratings on Negative Watch

(The following statement was released by the rating agency) CHICAGO, March 27 (Fitch) Fitch Ratings has placed Baxter International Inc.'s (Baxter; NYSE: BAX) long- and short-term ratings on Rating Watch Negative. The action follows the company's announcement that it plans to spin off its BioScience business. A full list of the company's ratings follows at the end of this press release. The ratings apply to approximately $9.11 billion of debt outstanding at Dec. 31, 2013. KEY RATING DRIVE

27 Mar 2014

Merck names Baxter exec as CFO

- Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.

27 Mar 2014

UPDATE 2-Merck names Baxter exec as CFO

March 27 - Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.

27 Mar 2014

Baxter plans to spin off biotech business in 2015

- Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.

27 Mar 2014

UPDATE 4-Baxter plans to spin off biotech business in 2015

March 27 - Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.

27 Mar 2014

Baxter plans to spin off biotech business in 2015

- Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.

27 Mar 2014

Merck appoints Baxter executive as CFO

- Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.

27 Mar 2014

CORRECTED-Merck appoints Baxter executive as CFO

(Corrects headline to show the Baxter executive is currently with, and not a former employee of, the company. Fixes spelling in first paragraph)

27 Mar 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $98.96 +0.21
Pfizer Inc. (PFE.N) $30.25 +0.16
Roche Holding Ltd. (ROG.VX) CHF254.90 +0.70
Abbott Laboratories (ABT.N) $38.93 +0.55
Boston Scientific Corporation (BSX.N) $13.65 +0.15
Wyeth Limited (WLED.NS) Rs844.85 -0.15
Hospira, Inc. (HSP.N) $42.84 -0.16

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks